Edition:
United Kingdom

Tocagen Inc (TOCA.OQ)

TOCA.OQ on NASDAQ Stock Exchange Global Select Market

13.94USD
8:59pm GMT
Change (% chg)

$0.31 (+2.27%)
Prev Close
$13.63
Open
$13.55
Day's High
$14.40
Day's Low
$13.33
Volume
66,392
Avg. Vol
63,862
52-wk High
$17.75
52-wk Low
$8.64

Chart for

About

Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to... (more)

Overall

Beta: --
Market Cap(Mil.): $206.81
Shares Outstanding(Mil.): 19.81
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.62
EPS (TTM): -- -- --
ROI: -- 3.19 10.61
ROE: -- 4.52 14.21

BRIEF-Tocagen Estimates Cash, Cash Equivalents And Marketable Securities About $89.0 Million As Of Dec 31, 2017

* TOCAGEN SAYS ESTIMATE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE ABOUT $89.0 MILLION AS OF DEC 31, 2017 - SEC FILING

08 Jan 2018

BRIEF-Tocagen Q3 loss per share $0.50

* Tocagen reports third quarter 2017 financial and business results

08 Nov 2017

BRIEF-Tocagen to accelerate Toca 511 & Toca FC development into Phase 3 trial

* Tocagen to accelerate Toca 511 & Toca FC development into pivotal Phase 3 trial Source text for Eikon: Further company coverage:

26 Oct 2017

BRIEF-Tocagen Q2 loss per share $0.56

* Tocagen reports second quarter 2017 financial and business results

09 Aug 2017

BRIEF-Tocagen reports quarterly loss per share $0.56‍​

* Qtrly license revenue $10,000 versus $13,000 Source text: (http://bit.ly/2wuNluv) Further company coverage:

09 Aug 2017

BRIEF-Tocagen receives PRIME designation for Toca 511

* Tocagen receives European Medicines Agency Priority Medicines (PRIME) designation for Toca 511 in high grade Glioma Source text for Eikon: Further company coverage:

24 Jul 2017

Earnings vs. Estimates